HALIFAX, June 29, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a
developer of rapid diagnostic technology and solutions, reported today
on its financial results for the three and nine month periods ending
April 30, 2012.
"The Company's third quarter results reflect the lengthy sales cycle
that our sales partners are currently experiencing in international
markets. We believe that a number of the sales initiatives that are
currently underway will conclude successfully in the short term," said
Hermes Chan, CEO, MedMira Inc. "Subsequent to the close of the quarter
MedMira was successful in securing a substantial investment from
Andurja Beteiligungen AG that will fuel the Company's ongoing sales,
marketing and business development activities around the globe. This
investment also enabled the improvement of the Company's debt position
with the elimination of over $11.8 million in debt. With a greatly
improved financial position and global business development strategies
aligned for success, MedMira is poised for growth."
Third Quarter Financial Highlights
The Company recorded revenue from product sales of $189,398 as compared
to $295,534 for the same period last year. The decrease in sales was
due to higher number in Q3 of 2011 from a one-time sale in the Africa
market, along with weaker North American sales in Q3 of 2012.
The Company recorded increased revenue from Asia Pacific product sales
of $63,130 over the same period last year.
Gross profit for the quarter was $131,393 compared to $148,651 in the
same period in 2011.
Total operating expenses increased to $679,300 in the quarter ended
April 30, 2012, compared to $534,810 during the same period in 2011.
The increase in operating expenses is attributed to R&D expenses
associated with the US Army contract and other projects as well as
increased professional fees.
Subsequent to the close of the third quarter, the Company completed a $6
million equity investment from Andurja Beteiligungen AG. Additionally,
On June 12, 2012, MedMira announced that it had paid $1,806,481 to
reduce the Company's debt position by $11,834,592. The debt reduction
occurred through various compromise and negotiated debt holder
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under
the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's
rapid flow-through HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada. For more
information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible future
growth and new business opportunities. Actual events could materially
differ from those projected herein and depend on a number of factors
including, but not limited to, changing market conditions, successful
and timely completion of clinical studies, uncertainties related to the
regulatory approval process, establishment of corporate alliances and
other risks detailed from time to time in the company quarterly
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE MEDMIRA INC.
For further information:
Andrea Young, Corporate Communications